RxDoctor Payments Data

Michael Stiles, MD

Glaucoma Specialist · Overland Park, KSNPI 1356390546

Payments from drug & device makers

$488,449in general payments, 2019–2025

Across 508 payments — averaging $961.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Glaukos Corporation$247K
  • AbbVie$160K
  • Aerie Pharmaceuticals, Inc.$31K
  • Alcon Research LLC$31K
  • Alcon$15K
  • Ivantis, Inc$1K
  • plus $3K from 20 others
$20,470in research payments, 2019–2025

Across 3 payments — averaging $6823.33 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • NEW World Medical,inc.$20K
  • AbbVie$70

What the payments were for

  • Consulting fees$3,6329%
  • Speaking & faculty fees$28,84169%
  • Travel & lodging$930%
  • Food & beverage$8,89421%
  • Education$140%
  • Gifts$450%
  • Entertainment$1050%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few glaucoma specialist providers in Kansasto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$586,691
Medicare patients
1,225
Services billed
4,572

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost292$152,467
CombiganBrimonidine Tartrate/Timolol294$114,287
RestasisCyclosporine77$65,157
Alphagan PBrimonidine Tartrate106$45,548
RocklatanNetarsudil Mesylat/Latanoprost89$43,287
RhopressaNetarsudil Mesylate79$30,211
Prednisolone Acetate597$24,982
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat1,146$19,854
SimbrinzaBrinzolamide/Brimonidine Tart80$19,204
Latanoprost1,356$16,579
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol91$15,508
Travoprost72$14,724
VyzultaLatanoprostene Bunod37$13,513
XiidraLifitegrast14$11,928
Brimonidine Tartrate459$11,365

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Combigan, Restasis, Alphagan P$160,235$377,458769 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$30,988$73,498168 claims
AlconSimbrinza, Azopt$15,425$28,19099 claims
Bausch & Lomb Americas Inc.Vyzulta, Xiidra$229$25,44151 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$87$4,55922 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few glaucoma specialist providers in Kansason file to place this against a meaningful peer group, so we don't.

Other glaucoma specialist in Overland Park

Where these figures come from

Is this you, or does something look wrong? →